Orlistat Synonyms: (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;(-)-Tetrahydro

• Post Date:

  Sep 08,2015

• Expiry Date:

  Mar 06,2016

• Detailed Description:

  Orlistat
  Synonyms: (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;(-)-Tetrahydrolipstatin(EquivalentToOrlistat);Orlipastat
  CAS: 96829-58-2
  MF: C29H53NO5
  MW: 495.73
  Product Categories: Pharmaceutical Raw Materials;Miscellaneous Biochemicals;Antiobesity Agent;Chiral Reagents;Pharmaceuticals
  Chemical Properties Off-White Solid
  Usage An antiobesity agent. A pancreatic lipase inhibitor. Antiobesity agent. Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity.
  Packing:1kg/foil bag or as required
  
  2. Description:
  Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor,
  thereby reducing caloric intake.
  It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
  
  Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass,
  although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat.
  After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.
  
  The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).
  Longterm use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).

• Company:

  Shenzhen Simeiquan Bio-tech Co., Ltd.     [ China ]        

• Contact:

  sue@chembj.com

• Tel:

  +86-18038176812

• Fax:

  +86-18038176812

• Email:

  sue@chembj.com